Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India

20251 citationsJournal Articlediamond Open Access

Authors

Debmalya Sanyal · Anandalok Hospital

Banshi Saboo · Diabetes Care & Hormone Clinic

Sanjeev Phatak · Swasthya Diabetes Care

Prasanna Kumar · Bangalore Diabetes Centre

Debasis Basu · Tata Medical Center

Nikhil Verma · ESIC Hospital

ARJUN NAIR ·

Abstract

Individuals with T2D treated with once-daily oral semaglutide experienced significant reductions in HbA<sub>1c</sub> and body weight, without any new safety events. These findings will add to the decision-making for initiating oral semaglutide in individuals with T2D in India.<b>Trial registration:</b> NCT05502562.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes, Cardiovascular Risks, and Lipoproteins

Publication Details

Published in: Indian Journal of Endocrinology and Metabolism

Volume 29, Issue 5, pp. 523-530

DOI: 10.4103/ijem.ijem_179_25

Field-Weighted Citation Impact: 1.36

Command Palette

Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India

Authors

Abstract

Topics & Keywords

Publication Details